These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27433783)

  • 1. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
    Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
    Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
    [No Abstract]   [Full Text] [Related]  

  • 2. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E
    Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688
    [No Abstract]   [Full Text] [Related]  

  • 3. Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil.
    Gouillon L; Perier-Muzet M; Amini-Adle M; Poulalhon N; Debarbieux S; Boespflug A; Balme B; Depaepe L; Harou O; Lopez J; Bringuier PP; Ferraro-Peyret C; Maucort-Boulch D; Robinson P; Thomas L; Dalle S
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e57-e59. PubMed ID: 31442328
    [No Abstract]   [Full Text] [Related]  

  • 4. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
    Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
    J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric melanoma: the whole (genome) story.
    Pappo AS
    Am Soc Clin Oncol Educ Book; 2014; ():e432-5. PubMed ID: 24857134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Carlino MS; Haydu LE; Kakavand H; Menzies AM; Hamilton AL; Yu B; Ng CC; Cooper WA; Thompson JF; Kefford RF; O'Toole SA; Scolyer RA; Long GV
    Br J Cancer; 2014 Jul; 111(2):292-9. PubMed ID: 24918823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular profile of metastatic melanoma in Australia.
    Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
    Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of BRAF and NRAS mutations in fast-growing melanomas.
    Nagore E; Hacker E; Martorell-Calatayud A; Traves V; Guillen C; Hayward NK; Whiteman D
    Pigment Cell Melanoma Res; 2013 May; 26(3):429-31. PubMed ID: 23448684
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population.
    Evrenos MK; Temiz P; Çam FS; Yaman M; Yoleri L; Ermertcan AT
    Turk J Med Sci; 2018 Oct; 48(5):973-979. PubMed ID: 30384563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of somatic mutational profile in multiple primary melanomas.
    Adler NR; McLean CA; Wolfe R; Kelly JW; McArthur GA; Haydon A; Tra T; Cummings N; Mar VJ
    Pigment Cell Melanoma Res; 2018 Sep; 31(5):592-603. PubMed ID: 29603877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIT, NRAS, and BRAF mutations in nail apparatus melanoma.
    Dika E; Altimari A; Patrizi A; Gruppioni E; Fiorentino M; Piraccini BM; Misciali C; Barisani A; Fanti PA
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):758-60. PubMed ID: 23782496
    [No Abstract]   [Full Text] [Related]  

  • 18. Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.
    Zebary A; Omholt K; van Doorn R; Ghiorzo P; Harbst K; Hertzman Johansson C; Höiom V; Jönsson G; Pjanova D; Puig S; Scarra GB; Harland M; Olsson H; Egyhazi Brage S; Palmer J; Kanter-Lewensohn L; Vassilaki I; Hayward NK; Newton-Bishop J; Gruis NA; Hansson J;
    J Invest Dermatol; 2014 Jan; 134(1):287-290. PubMed ID: 23771122
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Adler NR; Wolfe R; Kelly JW; Haydon A; McArthur GA; McLean CA; Mar VJ
    Br J Cancer; 2017 Sep; 117(7):1026-1035. PubMed ID: 28787433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma.
    Barel F; Guibourg B; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Acta Derm Venereol; 2018 Jan; 98(1):44-49. PubMed ID: 28660280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.